Relapsed or Refractory Follicular and Mantle Cell Lymphomas: Pharmacist-Driven Strategies to Optimize Patient Management

Relapsed or Refractory Follicular and Mantle Cell Lymphomas: Pharmacist-Driven Strategies to Optimize Patient Management

July 7, 2020

Specialty Pharmacy Times, June 2020, Volume 3, Issue 2

At the completion of this activity, the participant will be able to determine appropriate treatment options for a patient with relapsed or refractory FL or MCL.

THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM PHARMACYCLICS LLC, AN ABBVIE COMPANY AND JANSSEN BIOTECH, INC., AND CELGENE CORPORATION.

FACULTY

Deborah A. Hass, PharmD, BCOP, BCPS

Associate Professor of Pharmacy Practice

West Coast University School of Pharmacy

Los Angeles, California

At the completion of this activity, the participant will be able to:

Explain the role of prognostic indexes in treatment selection for patients with relapsed or refractory follicular lymphoma (FL) and mantle cell lymphoma (MCL)
Determine appropriate treatment options for a patient with relapsed or refractory FL or MCL based on disease- and patient-specific characteristics
Identify supportive care needs and medication adherence strategies for a patient with relapsed or refractory FL or MCL

TARGET AUDIENCE: Clinical pharmacists, specialty pharmacists, and oncology pharmacists

ACTIVITY TYPE:Application

RELEASE DATE: June 15, 2020EXPIRATION DATE: January 15, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.